Skip to main
INSM
INSM logo

Insmed (INSM) Stock Forecast & Price Target

Insmed (INSM) Analyst Ratings

Based on 31 analyst ratings
Buy
Strong Buy 39%
Buy 52%
Hold 6%
Sell 3%
Strong Sell 0%

Bulls say

Insmed Inc. is positioned for significant growth, with a current total addressable market potentially ranging from 500,000 to 1 million diagnosed patients suffering from Mycobacterium Avium Complex lung disease. The company has reiterated its full-year 2025 global revenue guidance for its first commercial product, ARIKAYCE, estimating revenues between $405 million and $425 million, alongside high expectations for the forthcoming Brensocatib launch, which is anticipated to capture a peak sales opportunity of $8.2 billion in bronchiectasis. Additionally, Insmed’s expanded commercial infrastructure and ongoing pipeline developments, including potential label expansion for ARIKAYCE and promising prospects for its Treprostinil Palmitil Inhalation Powder, contribute to a multi-billion dollar valuation outlook for the company's future pipeline.

Bears say

Insmed Inc faces significant financial challenges highlighted by a substantial net loss of $235.5 million for the fourth quarter of 2024 and $913.8 million for the full year, indicating ongoing operational difficulties. Furthermore, the company encounters various risks, including potential delays in regulatory approvals, safety events affecting drug efficacy, and challenges in successfully commercializing its products, which could hinder revenue generation and impact future profitability. Additionally, with ongoing heavy investments in research and development and selling, general, and administrative expenses, Insmed may struggle to maintain financial stability if its commercial efforts do not achieve anticipated success.

Insmed (INSM) has been analyzed by 31 analysts, with a consensus rating of Buy. 39% of analysts recommend a Strong Buy, 52% recommend Buy, 6% suggest Holding, 3% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Insmed and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Insmed (INSM) Forecast

Analysts have given Insmed (INSM) a Buy based on their latest research and market trends.

According to 31 analysts, Insmed (INSM) has a Buy consensus rating as of Aug 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $87.87, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $87.87, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Insmed (INSM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.